PMID- 23331284
OWN - NLM
STAT- MEDLINE
DCOM- 20130703
LR  - 20221207
IS  - 1440-1819 (Electronic)
IS  - 1323-1316 (Linking)
VI  - 67
IP  - 1
DP  - 2013 Jan
TI  - Ecstasy (3, 4-methylenedioxymethamphetamine) use among Japanese rave population.
PG  - 12-9
LID - 10.1111/j.1440-1819.2012.02402.x [doi]
AB  - AIMS: The aim of this study was to examine the prevalence of 3, 
      4-methylenedioxymethamphetamine (MDMA) use and to identify characteristics of 
      MDMA users among rave attendees in Japan. This is the first rave-population study 
      focusing on MDMA use in Japan. METHODS: The anonymous self-administrative 
      questionnaire was conducted using laptop computers at four rave parties at three 
      different venues in Tokyo, Japan. Participants were asked about lifetime use of 
      MDMA and other club drug use, characteristics of rave attendance, and their 
      demographics. RESULTS: Questionnaires were completed by 300 rave attendees (47.3% 
      female), 68.3% of whom were aged 20-29 years, and 92.3% of whom had completed 
      high school. Among the participants, 8.0% reported MDMA use. Compared with 
      'non-drug controls' (the participants who had never used any illicit drugs), MDMA 
      users were significantly more likely to be 30-39-year-old men. In addition, 
      compared with 'cannabis users' (non-MDMA users who had used cannabis), MDMA users 
      were significantly more likely to use other drugs and reported more adverse 
      health effects due to 'polydrug use'. Furthermore, MDMA users were significantly 
      more likely to go to raves and preferred smaller venues. CONCLUSIONS: Our results 
      clearly suggest that rave attendees have a higher lifetime prevalence of MDMA use 
      than the Japanese general population (0.2% reported in 2007). MDMA users are 
      deeply involved in rave parties, and MDMA use may have high potential to generate 
      close relationships among rave attendees. Therefore, MDMA users may have more 
      opportunities to access MDMA than cannabis users and non-drug controls.
CI  - (c) 2013 The Authors. Psychiatry and Clinical Neurosciences (c) 2013 Japanese Society 
      of Psychiatry and Neurology.
FAU - Shimane, Takuya
AU  - Shimane T
AD  - Department of Drug Dependence Research, National Institute of Mental Health, 
      National Center of Neurology and Psychiatry, Tokyo, Japan. shimane@ncnp.go.jp
FAU - Hidaka, Yasuharu
AU  - Hidaka Y
FAU - Wada, Kiyoshi
AU  - Wada K
FAU - Funada, Masahiko
AU  - Funada M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Psychiatry Clin Neurosci
JT  - Psychiatry and clinical neurosciences
JID - 9513551
RN  - 0 (Illicit Drugs)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Amphetamine-Related Disorders/*epidemiology
MH  - Asian People
MH  - Drug Users/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - *Illicit Drugs
MH  - Japan
MH  - Male
MH  - *N-Methyl-3,4-methylenedioxyamphetamine
MH  - Prevalence
MH  - Surveys and Questionnaires
EDAT- 2013/01/22 06:00
MHDA- 2013/07/05 06:00
CRDT- 2013/01/22 06:00
PHST- 2012/01/19 00:00 [received]
PHST- 2012/09/21 00:00 [revised]
PHST- 2012/09/26 00:00 [accepted]
PHST- 2013/01/22 06:00 [entrez]
PHST- 2013/01/22 06:00 [pubmed]
PHST- 2013/07/05 06:00 [medline]
AID - 10.1111/j.1440-1819.2012.02402.x [doi]
PST - ppublish
SO  - Psychiatry Clin Neurosci. 2013 Jan;67(1):12-9. doi: 
      10.1111/j.1440-1819.2012.02402.x.